SCHEMBL1307316

SCHEMBL1307316

CC(C)(C)OC(=O)N1CCC(N[C]=O)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.60
ALDH1A1 P00352 2/20 0.52
HPGD P15428 1/20 0.51
MAPT P10636 2/20 0.51
NPC1 O15118 1/20 0.51
MAPK1 P28482 1/20 0.51
HTT P42858 1/20 0.51
RAB9A P51151 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
RECQL P46063 1/20 0.49
PTPN2 P17706 1/20 0.48
PTPN1 P18031 1/20 0.48
PTPN6 P29350 1/20 0.48
USP2 O75604 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
GPR119 Q8TDV5 3/20 0.46
EPHX2 P34913 2/20 0.46
STS P08842 2/20 0.45
KDM4E B2RXH2 2/20 0.45
THRB P10828 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22755470 0.86 EPHX1 (0.58) EPHX1ALDH1A1HPGDMAPTNPC1
SCHEMBL770648 0.83 EPHX1 (0.47) EPHX1ALDH1A1L3MBTL1USP2EPHX2
SCHEMBL743999 0.81 EPHX1 (0.65) EPHX1ALDH1A1HPGDMAPTNPC1
SCHEMBL12061480 0.81 EPHX1 (0.65) EPHX1ALDH1A1HPGDMAPTNPC1
SCHEMBL215297 0.81 EPHX1 (0.65) EPHX1ALDH1A1HPGDMAPTNPC1
SCHEMBL24827741 0.80 EPHX1 (0.68) EPHX1ALDH1A1HPGDMAPTNPC1
SCHEMBL12819952 0.80 EPHX1 (0.63) EPHX1ALDH1A1HPGDMAPTNPC1
SCHEMBL1128308 0.80 EPHX1 (0.63) EPHX1ALDH1A1HPGDMAPTNPC1
SCHEMBL14768741 0.80 EPHX1 (0.63) EPHX1ALDH1A1HPGDMAPTNPC1
SCHEMBL22759160 0.79 EPHX1 (0.61) EPHX1ALDH1A1HPGDMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8053457-B2 3-imidazolyl-indoles for the treatment of proliferative diseases NOVARTIS AG (CH) 2011-11-08 US claimed
US-20100125064-A1 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases NOVARTIS AG (CH) 2010-05-20 US claimed
EP-2142535-A2 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES Novartis Ag (CH) 2010-01-13 EP claimed
WO-2008119741-A2 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2008-10-09 WO claimed
US-8053457-B2 3-imidazolyl-indoles for the treatment of proliferative diseases NOVARTIS AG (CH) 2011-11-08 US disclosed
US-20100125064-A1 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases NOVARTIS AG (CH) 2010-05-20 US disclosed
EP-2142535-A2 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES Novartis Ag (CH) 2010-01-13 EP disclosed
WO-2008119741-A2 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100125064-A1 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases MDM4, TP53, MDM2 EPHX1 3643/4885ALDH1A1 2589/4885HPGD 1961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.